Orally efficacious NR2B-selective NMDA receptor antagonists

被引：51
|
作者：
Claiborne, CF
McCauley, JA [1 ]
Libby, BE
Curtis, NR
Diggle, HJ
Kulagowski, JJ
Michelson, SR
Anderson, KD
Claremon, DA
Freidinger, RM
Bednar, RA
Mosser, SD
Gaul, SL
Connolly, TM
Condra, CL
Bednar, B
Stump, GL
Lynch, JJ
Macaulay, A
Wafford, KA
Koblan, KS
Liverton, NJ
机构：
[1] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA
[2] Merck Sharp & Dohme Res Labs, Dept Med Chem, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England
[3] Merck Res Labs, Dept Mol Pharmacol, W Point, PA 19486 USA
[4] Merck Sharp & Dohme Res Labs, Dept Pharmacol, W Point, PA 19486 USA
[5] Merck Sharp & Dohme Res Labs, Dept Pharmacol, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 04期
关键词：
D O I：
10.1016/S0960-894X(02)01061-2
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A novel series of benzamidines as synthesized and shogun to exhibit NR2B-subtype selective NMDA antagonist activity. Compound 31 is orally active in a carrageenan-induced rat hyperalgesia model of pain and shows no motor coordination side effects. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：697 / 700
页数：4
相关论文
共 50 条
  • [41] Amygdala infusions of an NR2B-selective or an NR2A-preferring NMDA receptor antagonist differentially influence fear conditioning and expression in the fear-potentiated startle test
    Walker, David L.
    Davis, Michael
    LEARNING & MEMORY, 2008, 15 (02) : 67 - 74
  • [42] Evidence for two classes of NR2B-directed NMDA receptor antagonists
    Chazot, PL
    Lawrence, S
    Thompson, CL
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135
  • [43] Discovery of 2,2-difluoro-2-phenylethyl-piperidines as NR2B-subtype selective NMDA receptor antagonists
    Kelly, Michael J., III
    Layton, M.
    Armstrong, D.
    Butcher, J.
    Claiborne, C.
    Claremon, D.
    Hartman, G.
    Libby, B.
    Liverton, N.
    McCauley, J.
    McIntyre, C.
    Munson, P.
    Nguyen, K.
    Phillips, B.
    Rodzinak, K.
    Romano, J.
    Sanderson, P.
    Schreier, J.
    Thompson, W.
    Yaroschak, M.
    Young, S.
    Bednar, B.
    Bednar, R.
    Chapman, K.
    Cunningham, M.
    DiLella, A.
    Gaul, S.
    Kane, S.
    Koblan, K.
    Leonard, Y.
    Liang, A.
    Lyle, E.
    Lynch, J.
    Mosser, S.
    Reiss, D.
    Stump, G.
    Sun, H.
    Wang, H.
    Xia, M.
    Addy, C.
    Shadle, C.
    Stone, J.
    Stroh, M.
    Fandozzi, C.
    Ellis, J.
    Gundersdorf, R.
    Trainor, N.
    Yergey, J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [44] Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1
    Tavares, Francis X.
    Al-Barazanji, Kamal A.
    Bigham, Eric C.
    Bishop, Michael J.
    Britt, Christy S.
    Carlton, David L.
    Feldman, Paul L.
    Goetz, Aaron S.
    Grizzle, Mary K.
    Guo, Yu C.
    Handlon, Anthony L.
    Hertzog, Donald L.
    Ignar, Diane M.
    Lang, Daniel G.
    Ott, Ronda J.
    Peat, Andrew J.
    Zhou, Hui-Qiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) : 7095 - 7107
  • [45] Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites
    Kawai, Makoto
    Sakurada, Isao
    Morita, Asato
    Iwamuro, Yuko
    Ando, Kazuo
    Omura, Hirofumi
    Sakakibara, Sachiko
    Masuda, Tsutomu
    Koike, Hiroki
    Honma, Teruki
    Hattori, Kazunari
    Takashima, Tadayuki
    Mizuno, Kunihiko
    Mizutani, Mayumi
    Kawamura, Mitsuhiro
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (20) : 5537 - 5542
  • [46] NR2B selective NMDA antagonists:: The evolution of the ifenprodil-type pharmaeophore
    Borza, Istvan
    Domany, Gyorgy
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (07) : 687 - 695
  • [47] Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease
    Tallaksen-Greene, Sara J.
    Janiszewska, Anita
    Benton, Kasha
    Ruprecht, Lech
    Albin, Roger L.
    EXPERIMENTAL NEUROLOGY, 2010, 225 (02) : 402 - 407
  • [48] Effects of distinct classes of N-methyl-D-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro:: suppression by NR2B-selective antagonists
    Wang, XM
    Bausch, SB
    NEUROPHARMACOLOGY, 2004, 47 (07) : 1008 - 1020
  • [49] 4-aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists
    Pinard, E
    Alanine, A
    Bourson, A
    Büttelmann, B
    Heitz, MP
    Mutel, V
    Gill, R
    Trube, G
    Wyler, R
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (18) : 2615 - 2619
  • [50] From Bradykinin B2 Receptor Antagonists to Orally Active and Selective Bradykinin B1 Receptor Antagonists
    Barth, Martine
    Bondoux, Michel
    Luccarini, Jean-Michel
    Peyrou, Vincent
    Dodey, Pierre
    Pruneau, Didier
    Massardier, Christine
    Paquet, Jean-Luc
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (06) : 2574 - 2584
12345